Latest News
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
21 May 2026 - Health and wellness platform Hims & Hers Health Inc (NYSE:HIMS) announced on Thursday that it has launched access to generic semaglutide through its platform in Canada, marking its first international generic GLP-1 offering.The comp...
Bayer's KERENDIA receives FDA priority review for type 1 diabetes and kidney disease treatment
21 May 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) announced on Thursday that the US Food and Drug Administration (FDA) has accepted and granted Priority Review to its supplemental New Drug Application for K...
Circio files new patent application for circVec gene therapy platform
21 May 2026 - Biotechnology company Circio Holding ASA (OSE:CRNA) announced on Thursday that it has filed a patent application with the European Patent Office covering a novel genetic element designed to enhance the performance of its circVec circula...
Upsher-Smith launches generic Cyclosporine Ophthalmic Emulsion 0.05%
21 May 2026 - Upsher-Smith Laboratories LLC, a subsidiary of Bora Pharmaceuticals Co Ltd (TW:6472 and OTCQX:BORAY), announced on Wednesday that it has launched its Cyclosporine Ophthalmic Emulsion 0.05%, therapeutically equivalent to the Reference Li...
BioMarin Pharmaceutical meets primary endpoint in Phase 3 study of VOXZOGO in children with hypochondroplasia
21 May 2026 - Rare disease biotechnology company BioMarin Pharmaceutical Inc (Nasdaq:BMRN) announced on Wednesday that the Phase 3 CANOPY-HCH-3 study evaluating treatment with VOXZOGO (vosoritide) in children with hypochondroplasia met its primary en...